Replimune Group (REPL) Competitors $9.34 -0.31 (-3.21%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$9.44 +0.11 (+1.12%) As of 07/8/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL vs. MOR, KYMR, ALVO, IMVT, CRNX, CPRX, HCM, AMRX, MIRM, and OGNShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include MorphoSys (MOR), Kymera Therapeutics (KYMR), Alvotech (ALVO), Immunovant (IMVT), Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Its Competitors MorphoSys Kymera Therapeutics Alvotech Immunovant Crinetics Pharmaceuticals Catalyst Pharmaceuticals HUTCHMED Amneal Pharmaceuticals Mirum Pharmaceuticals Organon & Co. Replimune Group (NASDAQ:REPL) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends. Does the media refer more to REPL or MOR? In the previous week, Replimune Group had 4 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Replimune Group and 1 mentions for MorphoSys. Replimune Group's average media sentiment score of 0.44 beat MorphoSys' score of -0.71 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Which has better valuation & earnings, REPL or MOR? MorphoSys has higher revenue and earnings than Replimune Group. MorphoSys is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$247.30M-$3.07-3.04MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Is REPL or MOR more profitable? Replimune Group has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Replimune Group's return on equity of -57.98% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -57.98% -45.21% MorphoSys -226.79%-694.31%-22.55% Which has more risk & volatility, REPL or MOR? Replimune Group has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Do analysts rate REPL or MOR? Replimune Group currently has a consensus price target of $20.83, indicating a potential upside of 123.05%. Given Replimune Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Replimune Group is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in REPL or MOR? 92.5% of Replimune Group shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 8.8% of Replimune Group shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryReplimune Group beats MorphoSys on 12 of the 16 factors compared between the two stocks. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$743.89M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-3.0420.8027.0020.10Price / SalesN/A286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book1.737.487.985.56Net Income-$247.30M-$55.04M$3.16B$248.40M7 Day Performance-2.20%2.44%2.40%4.67%1 Month Performance-8.25%1.90%2.19%6.64%1 Year Performance6.14%4.35%33.82%21.31% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group4.1647 of 5 stars$9.34-3.2%$20.83+123.1%+10.7%$743.89MN/A-3.04210MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730KYMRKymera Therapeutics3.1604 of 5 stars$43.64-1.1%$59.61+36.6%+35.9%$2.84B$47.07M-14.08170ALVOAlvotech3.5802 of 5 stars$9.12-0.2%$18.00+97.4%-27.5%$2.75B$491.98M24.651,032IMVTImmunovant1.3868 of 5 stars$16.00-0.6%$38.33+139.6%-38.9%$2.73BN/A-5.84120News CoverageCRNXCrinetics Pharmaceuticals3.1457 of 5 stars$28.76-4.0%$74.56+159.2%-35.3%$2.69B$1.04M-7.53210CPRXCatalyst Pharmaceuticals4.8978 of 5 stars$21.70-0.4%$32.83+51.3%+34.3%$2.65B$534.65M13.8280HCMHUTCHMED1.3224 of 5 stars$15.05-0.3%$19.00+26.2%-4.6%$2.62B$630.20M0.001,811AMRXAmneal Pharmaceuticals3.1277 of 5 stars$8.09-0.5%$11.60+43.4%+21.0%$2.54B$2.83B-202.208,100High Trading VolumeMIRMMirum Pharmaceuticals3.8633 of 5 stars$50.89-0.4%$65.50+28.7%+40.0%$2.52B$336.89M-31.61140Analyst DowngradeOGNOrganon & Co.4.8886 of 5 stars$9.68-1.8%$18.00+86.0%-50.6%$2.52B$6.40B3.364,000Trending News Related Companies and Tools Related Companies MorphoSys Alternatives Kymera Therapeutics Alternatives Alvotech Alternatives Immunovant Alternatives Crinetics Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives HUTCHMED Alternatives Amneal Pharmaceuticals Alternatives Mirum Pharmaceuticals Alternatives Organon & Co. Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REPL) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
